tetano
Editor, Senior Moderator
Sci Rep
. 2025 Apr 24;15(1):14348.
doi: 10.1038/s41598-025-95122-7. sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
David M Smadja[SUP] #[/SUP][SUP] 1 2 [/SUP], Clément R Massonnaud[SUP] #[/SUP][SUP] 3 4 [/SUP], Aurélien Philippe[SUP] #[/SUP][SUP] 5 6 [/SUP], Mickael Rosa[SUP] #[/SUP][SUP] 7 [/SUP], Sophie Luneau[SUP] 6 [/SUP], Antoine Rauch[SUP] 7 [/SUP], Nathan Peiffer-Smadja[SUP] 4 8 [/SUP], Amandine Gagneux-Brunon[SUP] 9 10 [/SUP], Julien Poissy[SUP] 7 [/SUP], Maxime Gruest[SUP] 6 [/SUP], Alexandre Ung[SUP] 7 [/SUP], Valérie Pourcher[SUP] 11 [/SUP], François Raffi[SUP] 12 [/SUP], Lionel Piroth[SUP] 13 [/SUP], Kévin Bouiller[SUP] 14 [/SUP], Hélène Esperou[SUP] 15 [/SUP], Christelle Delmas[SUP] 4 [/SUP], Drifa Belhadi[SUP] 3 4 [/SUP], Alpha Diallo[SUP] 16 [/SUP], Juliette Saillard[SUP] 16 [/SUP], Aline Dechanet[SUP] 3 4 [/SUP], Noémie Mercier[SUP] 16 [/SUP], Axelle Dupont[SUP] 4 8 [/SUP], François-Xavier Lescure[SUP] 4 8 [/SUP], François Goehringer[SUP] 17 [/SUP], Stéphane Jaureguiberry[SUP] 18 19 [/SUP], François Danion[SUP] 20 [/SUP], Violaine Tolsma[SUP] 21 [/SUP], André Cabie[SUP] 22 23 [/SUP], Johan Courjon[SUP] 24 25 [/SUP], Sylvie Leroy[SUP] 26 27 28 [/SUP], Joy Mootien[SUP] 29 [/SUP], Bruno Mourvillier[SUP] 30 [/SUP], Sébastien Gallien[SUP] 31 32 [/SUP], Jean-Philippe Lanoix[SUP] 33 34 [/SUP], Elisabeth Botelho-Nevers[SUP] 9 10 [/SUP], Florent Wallet[SUP] 35 [/SUP], Jean-Christophe Richard[SUP] 36 37 [/SUP], Jean Reuter[SUP] 38 [/SUP], Alexandre Gaymard[SUP] 39 40 [/SUP], Richard Greil[SUP] 41 [/SUP], Guillaume Martin-Blondel[SUP] 42 43 [/SUP], Claire Andrejak[SUP] 44 [/SUP], Yazdan Yazdanpanah[SUP] 4 8 [/SUP], Charles Burdet[SUP] 3 4 [/SUP], Jean-Luc Diehl[SUP] 5 45 [/SUP], Maya Hites[SUP] 46 [/SUP], Florence Ader[SUP] 47 48 [/SUP], Sophie Susen[SUP] 7 [/SUP], France Mentré[SUP] #[/SUP][SUP] 3 4 [/SUP], Annabelle Dupont[SUP] #[/SUP][SUP] 7 [/SUP]; Discovery Study Group
Collaborators, Affiliations
We investigated whether baseline levels of biomarkers related to endotheliopathy, thromboinflammation, and fibrosis were associated with clinical outcomes in hospitalized COVID-19 patients. We analyzed the associations between baseline levels of 21 biomarkers and time to hospital discharge and change in NEWS-2 score in patients from DisCoVeRy trial. We fitted multivariate models adjusted for baseline ISARIC 4C score, disease severity, D-dimer values, and treatment regimen. Between March 22 and June 29, 2020, 603 participants were randomized; 454 had a sample collected at baseline and analyzed. The backward selection of multivariate models showed that higher baseline levels of soluble suppressor of tumorigenicity 2 (sST2) and nucleosomes were statistically associated with a lower chance of hospital discharge before day 29 (sST2: aHR 0.24, 95% CI [0.15-0.38], p < 10[SUP]-9[/SUP]; nucleosomes: aHR 0.62, 95% CI [0.48-0.81], p < 10[SUP]-3[/SUP]). Likewise, higher levels of baseline sST2 were statistically associated with lower changes in the NEWS-2 score between baseline and day 15 (adjusted beta 4.47, 95% CI [2.65-6.28], p < 10[SUP]-5[/SUP]). Moreover, we evaluated sST2 involvement in a confirmation cohort (SARCODO study, 103 patients) and found that elevated baseline sST2 levels were significantly associated with lower rates of hospital discharge before day 29 and a higher model performance (AUC at day 29 of 92%) compared to models without sST2. sST2 emerged as an independent predictor of clinical outcomes in two large cohort of hospitalized COVID-19 patients, warranting further investigation to elucidate its role in disease progression and potential as a therapeutic target.
Keywords: Angiogenesis; COVID-19; Fibrosis; SARS-CoV-2; ST2.
. 2025 Apr 24;15(1):14348.
doi: 10.1038/s41598-025-95122-7. sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
David M Smadja[SUP] #[/SUP][SUP] 1 2 [/SUP], Clément R Massonnaud[SUP] #[/SUP][SUP] 3 4 [/SUP], Aurélien Philippe[SUP] #[/SUP][SUP] 5 6 [/SUP], Mickael Rosa[SUP] #[/SUP][SUP] 7 [/SUP], Sophie Luneau[SUP] 6 [/SUP], Antoine Rauch[SUP] 7 [/SUP], Nathan Peiffer-Smadja[SUP] 4 8 [/SUP], Amandine Gagneux-Brunon[SUP] 9 10 [/SUP], Julien Poissy[SUP] 7 [/SUP], Maxime Gruest[SUP] 6 [/SUP], Alexandre Ung[SUP] 7 [/SUP], Valérie Pourcher[SUP] 11 [/SUP], François Raffi[SUP] 12 [/SUP], Lionel Piroth[SUP] 13 [/SUP], Kévin Bouiller[SUP] 14 [/SUP], Hélène Esperou[SUP] 15 [/SUP], Christelle Delmas[SUP] 4 [/SUP], Drifa Belhadi[SUP] 3 4 [/SUP], Alpha Diallo[SUP] 16 [/SUP], Juliette Saillard[SUP] 16 [/SUP], Aline Dechanet[SUP] 3 4 [/SUP], Noémie Mercier[SUP] 16 [/SUP], Axelle Dupont[SUP] 4 8 [/SUP], François-Xavier Lescure[SUP] 4 8 [/SUP], François Goehringer[SUP] 17 [/SUP], Stéphane Jaureguiberry[SUP] 18 19 [/SUP], François Danion[SUP] 20 [/SUP], Violaine Tolsma[SUP] 21 [/SUP], André Cabie[SUP] 22 23 [/SUP], Johan Courjon[SUP] 24 25 [/SUP], Sylvie Leroy[SUP] 26 27 28 [/SUP], Joy Mootien[SUP] 29 [/SUP], Bruno Mourvillier[SUP] 30 [/SUP], Sébastien Gallien[SUP] 31 32 [/SUP], Jean-Philippe Lanoix[SUP] 33 34 [/SUP], Elisabeth Botelho-Nevers[SUP] 9 10 [/SUP], Florent Wallet[SUP] 35 [/SUP], Jean-Christophe Richard[SUP] 36 37 [/SUP], Jean Reuter[SUP] 38 [/SUP], Alexandre Gaymard[SUP] 39 40 [/SUP], Richard Greil[SUP] 41 [/SUP], Guillaume Martin-Blondel[SUP] 42 43 [/SUP], Claire Andrejak[SUP] 44 [/SUP], Yazdan Yazdanpanah[SUP] 4 8 [/SUP], Charles Burdet[SUP] 3 4 [/SUP], Jean-Luc Diehl[SUP] 5 45 [/SUP], Maya Hites[SUP] 46 [/SUP], Florence Ader[SUP] 47 48 [/SUP], Sophie Susen[SUP] 7 [/SUP], France Mentré[SUP] #[/SUP][SUP] 3 4 [/SUP], Annabelle Dupont[SUP] #[/SUP][SUP] 7 [/SUP]; Discovery Study Group
Collaborators, Affiliations
- PMID: 40274842
- PMCID: PMC12022249
- DOI: 10.1038/s41598-025-95122-7
We investigated whether baseline levels of biomarkers related to endotheliopathy, thromboinflammation, and fibrosis were associated with clinical outcomes in hospitalized COVID-19 patients. We analyzed the associations between baseline levels of 21 biomarkers and time to hospital discharge and change in NEWS-2 score in patients from DisCoVeRy trial. We fitted multivariate models adjusted for baseline ISARIC 4C score, disease severity, D-dimer values, and treatment regimen. Between March 22 and June 29, 2020, 603 participants were randomized; 454 had a sample collected at baseline and analyzed. The backward selection of multivariate models showed that higher baseline levels of soluble suppressor of tumorigenicity 2 (sST2) and nucleosomes were statistically associated with a lower chance of hospital discharge before day 29 (sST2: aHR 0.24, 95% CI [0.15-0.38], p < 10[SUP]-9[/SUP]; nucleosomes: aHR 0.62, 95% CI [0.48-0.81], p < 10[SUP]-3[/SUP]). Likewise, higher levels of baseline sST2 were statistically associated with lower changes in the NEWS-2 score between baseline and day 15 (adjusted beta 4.47, 95% CI [2.65-6.28], p < 10[SUP]-5[/SUP]). Moreover, we evaluated sST2 involvement in a confirmation cohort (SARCODO study, 103 patients) and found that elevated baseline sST2 levels were significantly associated with lower rates of hospital discharge before day 29 and a higher model performance (AUC at day 29 of 92%) compared to models without sST2. sST2 emerged as an independent predictor of clinical outcomes in two large cohort of hospitalized COVID-19 patients, warranting further investigation to elucidate its role in disease progression and potential as a therapeutic target.
Keywords: Angiogenesis; COVID-19; Fibrosis; SARS-CoV-2; ST2.